• By Steven Muntner, Beth Allan, and Deanna Kamienski
Generate a summary of this article
Listen to this article
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2016.
Oxford Immunotec Global PLC is paying $6mm in cash to acquire Immunetics Inc. (immunoassays for infectious diseases). Oxford could also shell out up to $6mm in cash upon attaining certain revenue goals and development milestones over the next three years. (Oct.)
Immunetics offers rapid, cost-effective ELISA and Western Blot tests that are highly specific and sensitive. Its BacTx is a colorimetric...
Candid conversations with C-suite leaders.
Keep up with strategy, innovation and evolving trends across life science industries.
Without a mega-merger like 2023’s Pfizer/Seagan takeout, M&A deals grew smaller during the first half of 2024, while volume rose. In alliance deals, H1 2024 activity somewhat mirrored activity from H1 2023.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.